Therapeutic options for triple-negative breast cancers with defective homologous recombination.
about
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerDNA repair and personalized breast cancer therapyNew advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrenceNestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells.Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancerUpregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.Drug therapy for hereditary cancersClinical implications of the coexpression of SRC1 and NANOG in HER-2-overexpressing breast cancers.Cancer stem cells and early stage basal-like breast cancer.NOTCH1 is a poor prognostic factor for breast cancer and is associated with breast cancer stem cells.Cisplatin affects the conformation of apo form, not holo form, of BRCA1 RING finger domain and confers thermal stability.
P2860
Q24632628-1530A275-197D-4180-A5C5-33BB483893A3Q34234936-3849F25F-4829-45F3-86C4-2A75D237C826Q34382914-70E2DF50-5111-4FFA-8937-66016E57E487Q34452022-E10BA5EE-2F1E-46A9-91E5-0652E521FE7BQ34460831-F0AE4613-6B5D-4A5E-9784-68DA6C394B2BQ34887682-41196380-3ED5-4AD8-A40E-1D3E7252C3C6Q34972500-640DAE6C-064D-4183-9237-063D6A7F3FC7Q35064705-5CADAF1A-855D-4ABF-9835-5E65E44E8202Q35208929-9F89D4C2-28A4-43A2-82B8-3110D1553E8BQ37252336-E6504C38-098E-42CC-84D3-1E160EB09E15Q37660438-D7CBEEAB-5BF2-4A76-A696-5B3A4FB45CCFQ42369725-2B25B315-67ED-4D4D-9549-D7616B35F74DQ43537472-D001EDDD-AD70-4A49-BCE3-F84D7B195014
P2860
Therapeutic options for triple-negative breast cancers with defective homologous recombination.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic options for triple ...... tive homologous recombination.
@en
Therapeutic options for triple ...... tive homologous recombination.
@nl
type
label
Therapeutic options for triple ...... tive homologous recombination.
@en
Therapeutic options for triple ...... tive homologous recombination.
@nl
prefLabel
Therapeutic options for triple ...... tive homologous recombination.
@en
Therapeutic options for triple ...... tive homologous recombination.
@nl
P1476
Therapeutic options for triple ...... tive homologous recombination.
@en
P2093
Janneke E Jaspers
Jos Jonkers
P304
P356
10.1016/J.BBCAN.2009.07.001
P407
P577
2009-07-17T00:00:00Z